In PLOS this week: COLEC10 linked to craniofacial development, transcripts and peptides of spider venom, and more.
The WUSTL-developed method detects a bile acid that is found at increased levels in Niemann-Pick patients, and is ready for pilot testing, its developers said.
At next week's workshop on the validation of LC/MS-based protein and peptide tests, the FDA hopes to determine what it needs to demand from test developers.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
Scientists from the Okinawa Institute of Science and Technology and Kyoto University have found 14 metabolites whose levels differ in older individuals' blood.
The announcement comes as the agency is preparing to regulate laboratory developed tests as medical devices, including those based on mass spectrometry.
Advion is opening a new services facility in Indianapolis, and Eli Lilly will transition its drug discovery bioanalytical capability to the firm.
Bio-analytical segment revenues dipped 8 percent to $496 million, with life sciences down 5 percent to $234 million.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.